Clinical Trial Detail

NCT ID NCT02034916
Title A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors BioMarin Pharmaceutical
Indications

breast carcinoma

Therapies

Talazoparib

Age Groups: adult

Additional content available in CKB BOOST